Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Director Sells $423,350.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $84.67, for a total value of $423,350.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $85.42 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $39.21 and a fifty-two week high of $91.82. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analyst estimates of $94.00 million. During the same quarter in the previous year, the company earned ($0.51) EPS. analysts anticipate that Neurocrine Biosciences, Inc. will post -0.19 EPS for the current year.

Several large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its holdings in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after acquiring an additional 810 shares during the period. Amalgamated Bank increased its holdings in shares of Neurocrine Biosciences by 5.7% in the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock valued at $1,357,000 after acquiring an additional 947 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Neurocrine Biosciences by 25.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock valued at $458,000 after acquiring an additional 1,200 shares during the period. Finally, Grandfield & Dodd LLC grew its stake in Neurocrine Biosciences by 24.1% during the 3rd quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock worth $466,000 after buying an additional 1,480 shares during the last quarter.

A number of equities research analysts have weighed in on NBIX shares. Citigroup reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BMO Capital Markets lifted their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Deutsche Bank reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Oppenheimer lifted their target price on Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $90.79.

TRADEMARK VIOLATION NOTICE: This story was first reported by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/insider-selling-neurocrine-biosciences-inc-nbix-director-sells-423350-00-in-stock/1907365.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.